GW&K Investment Management LLC Sells 135,784 Shares of Artivion, Inc. $AORT

GW&K Investment Management LLC trimmed its holdings in Artivion, Inc. (NYSE:AORT) by 13.9% in the third quarter, Holdings Channel reports. The institutional investor owned 843,907 shares of the company’s stock after selling 135,784 shares during the period. GW&K Investment Management LLC’s holdings in Artivion were worth $35,731,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd raised its holdings in Artivion by 402.3% in the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. State of Wyoming acquired a new position in Artivion in the third quarter valued at about $80,000. Diversified Trust Co bought a new stake in Artivion during the third quarter worth about $200,000. Finally, Tower Research Capital LLC TRC grew its stake in Artivion by 447.6% during the second quarter. Tower Research Capital LLC TRC now owns 5,410 shares of the company’s stock worth $168,000 after buying an additional 4,422 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on AORT. Needham & Company LLC restated a “buy” rating and issued a $58.00 target price on shares of Artivion in a research report on Monday, February 2nd. Oppenheimer reissued an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Canaccord Genuity Group cut their target price on Artivion from $51.00 to $48.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Wall Street Zen downgraded Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Stifel Nicolaus set a $55.00 price target on Artivion in a report on Thursday. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $50.47.

Insider Activity

In related news, EVP Lance A. Berry sold 6,316 shares of Artivion stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $37.78, for a total transaction of $238,618.48. Following the sale, the executive vice president directly owned 210,827 shares in the company, valued at $7,965,044.06. This trade represents a 2.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John E. Davis sold 4,573 shares of the business’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $37.78, for a total transaction of $172,767.94. Following the sale, the insider directly owned 230,794 shares in the company, valued at $8,719,397.32. The trade was a 1.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 137,615 shares of company stock valued at $5,180,246. 7.60% of the stock is currently owned by company insiders.

Artivion News Roundup

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Quarterly results beat expectations (EPS and revenue) and showed ~19% YoY revenue growth, supporting the growth narrative and analyst conviction. MarketBeat – Artivion Earnings Summary
• Positive Sentiment: Management will present at the Oppenheimer Healthcare MedTech & Services Conference — a near‑term event where guidance, commercialization updates or product milestones could be disclosed and re‑ignite buy‑side interest. Artivion to Participate in Oppenheimer Conference
• Positive Sentiment: Large institutional buying (notably Invesco’s sizable Q4 add and other funds increasing exposure) can provide steadier bid support and signals professional investor confidence. MarketBeat – Institutional Activity
• Neutral Sentiment: Analyst coverage remains constructive (consensus “Moderate Buy” with elevated price targets), which helps sentiment but may already be priced in. MarketBeat – Analyst Ratings
• Neutral Sentiment: Industry pieces highlight portfolio expansion and relative EPS performance on the NYSE Composite — useful narrative fuel but not an immediate catalyst. Kalkine – Portfolio Expansion Article
• Negative Sentiment: Clustered insider selling March 2–4: CEO James Mackin sold 17,887 shares (~$676k), EVP Lance Berry sold ~6,316 shares (~$238k), other senior execs (SVPs, CAO Amy Horton and others) sold multiple tranches. Markets often interpret concentrated senior‑level sales as a negative near‑term signal despite insiders retaining large stakes. See filings and coverage. SEC Form 4 – Mackin Benzinga – CCO Trade Benzinga – Lance Berry Sale

Artivion Stock Performance

NYSE AORT opened at $37.87 on Friday. The firm’s fifty day moving average price is $41.24 and its two-hundred day moving average price is $42.88. The stock has a market cap of $1.81 billion, a PE ratio of 189.36 and a beta of 1.60. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. Artivion, Inc. has a fifty-two week low of $21.97 and a fifty-two week high of $48.25.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.03. The company had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.The business’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities analysts expect that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.